

Agnete Svendsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7360269/publications.pdf>

Version: 2024-02-01

41
papers

4,077
citations

331670

21
h-index

377865

34
g-index

44
all docs

44
docs citations

44
times ranked

6366
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 841447.	3.9	17
2	Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. <i>Frontiers in Oncology</i> , 2022, 12, 818437.	2.8	7
3	Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2022, 13, 869676.	4.8	24
4	Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 941.	3.7	20
5	Induction of alveolar and bronchiolar phenotypes in human lung organoids. <i>Physiological Reports</i> , 2021, 9, e14857.	1.7	4
6	Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. <i>Cancers</i> , 2021, 13, 533.	3.7	41
7	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 502 1,430	9.1	1,430
8	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. <i>IScience</i> , 2020, 23, 101649.	4.1	20
9	Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140.		1
10	Hypoxia-driven intratumor heterogeneity and immune evasion. <i>Cancer Letters</i> , 2020, 492, 1-10.	7.2	39
11	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	1.1	66
12	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
13	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 185, 57-70.	2.5	5
14	Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. <i>British Journal of Cancer</i> , 2019, 121, 545-555.	6.4	49
15	AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. <i>Cancer Immunology Research</i> , 2019, 7, 1789-1802.	3.4	52
16	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6.	5.0	51
17	Abstract 1200: AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells. , 2019, , .		0
18	Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. <i>Bulletin Du Cancer</i> , 2018, 105, 537-541.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 41.	3.7	22
20	Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS43-TPS43.	1.6	13
21	Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy. , 2018, , .		2
22	Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated <i>MGMT</i> promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux. <i>Cancer Research</i> , 2018, 78, 2928-2928.	0.9	3
23	The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. , 2017, , 351-376.		2
24	Adaptive mechanisms of resistance to anti-neoplastic agents. <i>MedChemComm</i> , 2017, 8, 53-66.	3.4	12
25	Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. <i>PLoS ONE</i> , 2017, 12, e0183254.	2.5	38
26	Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models. , 2017, , .		5
27	Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. , 2016, , .		5
28	Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy. , 2016, , .		1
29	Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18.	2.5	61
30	NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival. <i>Journal of Immunology</i> , 2014, 193, 6192-6206.	0.8	52
31	U251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. <i>Cancer Medicine</i> , 2014, 3, 812-824.	2.8	127
32	Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. <i>Acta Neuropathologica</i> , 2011, 122, 495-510.	7.7	125
33	Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. <i>PLoS ONE</i> , 2011, 6, e23062.	2.5	81
34	Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track – Letter. <i>Cancer Research</i> , 2010, 70, 6393-6396.	0.9	278
35	Glioma Cell Populations Grouped by Different Cell Type Markers Drive Brain Tumor Growth. <i>Cancer Research</i> , 2010, 70, 4274-4279.	0.9	77
36	Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation. <i>Cancer Research</i> , 2009, 69, 5331-5339.	0.9	590

#	ARTICLE	IF	CITATIONS
37	CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer, 2008, 122, 761-768.	5.1	508
38	The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene, 2008, 27, 5182-5194.	5.9	128
39	A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB Journal, 2008, 22, 3120-3128.	0.5	57
40	Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine, 2006, 8, 1131-1140.	2.8	19
41	Widespread Dispersion of Adeno-Associated Virus Serotype 1 and Adeno-Associated Virus Serotype 6 Vectors in the Rat Central Nervous System and in Human Glioblastoma Multiforme Xenografts. Human Gene Therapy, 2005, 16, 381-392.	2.7	26